Oral lipid prodrug V2043 (1- O -octadecyl-2- O -benzyl- sn -glyceryl-P-remdesivir nucleoside) protects mice from lethal dengue infection
Antimicrobial Agents and Chemotherapy · 2026
DOI: 10.1128/aac.00401-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Alex E Clark und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of California San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: Prodrugs, Antiviral Agents, Dengue, Alanine. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases, NIAID NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Dengue virus and related flaviviruses are significant threats to global health, with no approved antiviral treatments available. Remdesivir triphosphate (RVn-TP) is a nucleotide analog that inhibits RNA-dependent RNA polymerases from many clinically important RNA viruses, including dengue virus. An orally bioavailable prodrug that efficiently delivers RVn-TP could facilitate early treatment for non-hospitalized dengue patients. To that end, we developed 1- O -octadecyl-2- O -benzyl- sn -glyceryl-P-remdesivir nucleoside (V2043, ODBG-P-RVn), a phospholipid prodrug that achieves RVn-TP delivery through improved oral bioavailability, potency, and pharmacokinetics. Here, we show that when compared to the parent compound remdesivir nucleoside (RVn), V2043 is a more potent in vitro inhibitor of multiple flaviviruses, including dengue, Zika, West Nile, and Japanese encephalitis viruses. In lethal prophylactic and therapeutic mouse models that recapitulate key aspects of severe dengue in humans, once-daily oral V2043 significantly decreased dengue serum viremia, clinical severity, weight loss, and mortality. Additionally, oral V2043 was well tolerated when administered daily for 14 days. These results demonstrate the potential therapeutic efficacy of V2043 to treat several clinically relevant flaviviruses, including dengue virus, the most prevalent and widespread arbovirus infection in the world.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of California San Diego, La Jolla, California, USA.
- Department of Medicine, University of California San Diego, La Jolla, California, USA.
- Department of Pediatrics, University of California San Diego, La Jolla, California, USA.
- Department of Infectious Diseases, J. Craig Venter Institute, La Jolla, California, USA.
ORCID-Profile: Alex E Clark, Robert T Schooley, Karl Y Hostetler, Aaron F Carlin
Förderung
- National Institute of Allergy and Infectious Diseases
- NIAID NIH HHS
- NIGMS NIH HHS
- Bill and Melinda Gates Foundation
Zitieren
APA
Clark, A. E., Erlich, J. R., Beadle, J. R., McMillan, R. E., Xie, J., Garretson, A. F., Atkins, S., Sharma, A., Rajan, S. M., Croker, B. A., Schooley, R. T., Hostetler, K. Y., & Carlin, A. F. (2026). Oral lipid prodrug V2043 (1- O -octadecyl-2- O -benzyl- sn -glyceryl-P-remdesivir nucleoside) protects mice from lethal dengue infection. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00401-26
Vancouver
Clark AE, Erlich JR, Beadle JR, McMillan RE, Xie J, Garretson AF, et al. Oral lipid prodrug V2043 (1- O -octadecyl-2- O -benzyl- sn -glyceryl-P-remdesivir nucleoside) protects mice from lethal dengue infection. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.00401-26
BibTeX
@article{Clark2026,
author = {Clark, Alex E and Erlich, Jonathan R and Beadle, James R and McMillan, Rachel E and Xie, Jialei and Garretson, Aaron F and Atkins, Shae and Sharma, Anoushka and Rajan, Suraj Manohar and Croker, Ben A and Schooley, Robert T and Hostetler, Karl Y and Carlin, Aaron F},
title = {Oral lipid prodrug V2043 (1- O -octadecyl-2- O -benzyl- sn -glyceryl-P-remdesivir nucleoside) protects mice from lethal dengue infection},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.00401-26}
}
EUVIMED